 I. To assess response rates and survival parameters of patients treated with ABT-888 bendamustine - rituximab. Phase Ib II. To assess pharmacokinetic parameters of ABT-888 in this regimen. Phase Ib III. To assess progression-free survival, overall survival, and duration of remission of patients with indolent NHL and MCL treated with ABT-888 bendamustine rituximab. Phase IIa 